Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HB0043 in moderate to severe hidradenitis suppurativa
NCT06895499Phase 2Recruiting
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Jan 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of HB0043 in hidradenitis suppurativa (HS), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Started Mar 2025; status: recruiting.
02
Drugs
HB0043
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06895499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06895499.